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ABSTRACT
Objective: To analyse the neointimal coverage of
sirolimus-eluting stent (SES) and bare-metal stent (BMS)
visualised in vivo by optical coherence tomography (OCT).
Methods: OCT images were obtained in 26 coronary
vessels of 24 patients at 5–93 months after SES or BMS
deployment. The short-term BMS group (BMS1) con-
sisted of eight BMS in seven patients at 5–10 months of
follow-up, the long-term BMS group (BMS2) consisted of
six BMS in six patients at 23–93 months of follow-up,
and the SES group (SES) consisted of 13 SES in 10
patients at 6–12 months of follow-up. The strut apposi-
tion, strut coverage and mean maximal and minimal
neointimal thicknesses (NIT) for both BMS groups and
SES were compared.
Results: OCT images were acquired successfully.
Significant differences between completely apposed and
malapposed stent struts (p,0.0001) and between
covered and uncovered stent struts (p,0.0001) were
found among the three groups. The mean maximal and
minimal NIT in the SES group were all significantly less
than those of the BMS1 or BMS2 group, the minimal NIT
in the BMS1 group was significantly less than that of the
BMS2 but the mean maximal NIT was no significant
difference between the BMS1 and BMS2 groups. In an
open bifurcation artery, 19 struts visualised by OCT had no
discernible coverage or were surrounded by either
thrombus or a thick tissue layer.
Conclusions: OCT imaging can clearly visualise stent
apposition and neointimal coverage of stent struts.
Incomplete strut apposition and lack of strut coverage
occurred with a significantly higher frequency in SES than
in BMS. These findings may explain the occurrence of late
thrombosis in SES.
Optical coherence tomography (OCT) is the
optical analogue to ultrasound, measuring the
back-reflection of infrared light instead of sound
waves. The greatest advantage of OCT is its high
resolution, which exceeds that of any currently
available in vivo imaging technology. The resolu-
tion of catheter-based systems is in the range of
10–20 mm.
12 Furthermore, resolutions as high as
4 mm have been achieved ex vivo with more
sophisticated techniques that may be applicable
to future catheter-based approaches. The main
components of various atheromatous plaques can
be identified in OCT images, and have been
validated in a histology-controlled study.
3 Several
studies have demonstrated the feasibility of OCT
imaging in patients undergoing percutaneous
coronary intervention (PCI).
4–10 The aim of the
present study was to use OCT to analyse the
neointimal coverage of sirolimus-eluting stents
(SES), compared with that of bare-metal stents
(BMS).
METHODS
Study population
From July 2005 to November 2006, 24 patients (21
men and 3 women) at 5–93 months of follow-up
after SES or BMS implantation in a native coronary
artery were enrolled in the study after written
informed consent was obtained. Patients were
excluded if they had left main disease, ostial
disease, congestive heart failure or renal insuffi-
ciency with baseline serum creatinine .1.8 mg/dl
(.133 mmol/l). Coronary angiograms were
obtained from all patients before OCT imaging.
OCT images of 28 stents in 26 diseased coronary
vessels were obtained from the 24 patients. The
treated vessel segments were distributed as fol-
lows: 18 left anterior descending (LAD) lesions,
treated with 19 stents (68%); four left circumflex
(LCX) lesions, treated with five stents (18%); and
four right coronary artery (RCA) lesions, treated
with four stents (14%). An equal number of BMS
and SES (n=14; eight Cypher, Cordis Johnson &
Johnson and six Firebird, Microport) were
implanted among the study population. The
short-term BMS group (BMS1) consisted of eight
BMS in seven patients at 5–10 months follow-up.
The long-term BMS group (BMS2) consisted of six
BMS in six patients at 23–93 months of follow-up
and the SES group (SES), consisted of 13 SES in 10
patients at 6–12 months of follow-up. Antiplatelet
therapy consisted of clopidogrel for one month and
aspirin indefinitely for both BMS groups, and
clopidogrel for 12 months and aspririn indefinitely
for the SES group. One patient who experienced
acute anterior myocardial infarction 29 months
after SES stenting in the LAD was excluded from
the SES group.
OCT image acquisition
After coronary angiography, a 0.014 inch
(0.36 mm) guidewire was advanced through a 6Fr
guiding catheter into the desired vessel and across
the target location, and then a 4F Helios occlusion
balloon catheter (OBC, LightLab Imaging,
Westford, MA, USA) was advanced over the
guidewire into the vessel until the OBC tip marker
was distal to the target location. The guidewire
was removed from the OBC, and the 1.4F
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advanced to the OBC distal tip marker under fluoroscopic
guidance. While holding the ImageWire in place, the OBC was
retracted until the balloon marker was located proximal to the
target site. The contrast injection pump was turned on to start
the flow of flush solution at 0.5–0.6 ml/s through the OBC
lumen. The occlusion balloon was then inflated to 0.3–0.5 atm.
When an OCT image of the vessel wall appeared, a motorised
pullback was initiated from the imaging system console. At a
pullback rate of 1.0 mm/s (or 1.5 mm/s) and 15 frames/s, a
video sequence of cross-sectional OCT images over a 3 cm (or
4.5 cm) length of artery was obtained. After imaging was
complete, the balloon was deflated, and flow of flush solution
was stopped.
OCT data analysis
OCT images were analysed by two independent investigators
who were blinded to the clinical presentation. When there was
discordance between the observers, a non-blinded consensus
reading was completed. One OCT cross-sectional still frame
was selected for quantitative analysis from each 1 mm segment
throughout the entire length of each stent. The still frames were
selected based on appearance of stent struts, and lack of OCT
image artefacts such as motion artefacts. Each observed strut in
each analysed still frame was classified as either completely or
incompletely apposed, with a distance of >200 mm between the
strut inner-surface reflection and vessel wall defined to be
incomplete apposition. The surface of every strut was also
classified as either covered or uncovered. For each covered strut,
the maximal and minimal neointimal thicknesses (NIT) were
measured and these measurements were compiled to obtain the
mean maximal and minimal NIT for each stent. Finally, the
strut apposition, strut coverage and mean maximal and minimal
NIT for BMS and SES were compared.
Statistical analysis
Continuous data are expressed as mean (SD). Baseline
characteristics and measurements were analysed by use of the
Pearson x
2 test or one-way ANOVA, as appropriate. All analyses
were performed using a statistical software package (SPSS
version 11.5). A p value of (0.05 was specified as the confidence
level for statistical significance.
All imaging procedures were performed without complication
or adverse events.
RESULTS
Baseline characteristics
In the short-term BMS group (BMS1), the average time between
the stenting and OCT imaging follow-up was 7.29 (SD 2.06;
range 5–10) months, versus 44.50 (24.56; 23–93) months for the
Table 1 Baseline characteristics
Characteristic BMS1 BMS2 SES p Value
Cases 7 6 10
Age (years) 61.0 (10.49) 64.2 (7.78) 58.3 (9.82) 0.50
Time post-stenting (months) 7.29 (2.06) 44.50 (24.56) 8.60 (2.72) ,0.0001*
Male sex 6 6 8 0.51
Stent diameter (mm) 3.03 (0.34) 3.04 (0.25) 3.05 (0.28) 0.99
Stent length (mm) 18.75 (3.77) 17.50 (3.99) 22.00 (6.03) 0.15
Hypertension 5 6 8 0.38
Diabetes mellitus 1 2 6 0.16
Smoking 3 5 6 0.33
CHO (mmol/l) 4.33 (0.88) 4.03 (0.36) 4.51 (1.13) 0.50
TG (mmol/l) 1.37 (0.52) 2.08 (1.03) 2.00 (1.53) 0.77
HDL (mmol/l) 0.91 (0.43) 1.04 (0.09) 1.03 (0.22) 0.80
LDL (mmol/l) 2.81 (0.69) 2.35 (0.22) 2.88 (0.97) 0.39
OCT target vessel
LAD 4 4 9 0.24
LCX 1 0 3
RCA 2 2 0
BMS1 group, bare-metal stent with 5–10 months follow-up; BMS2 group, bare-metal stent with 23–93 months follow-up; SES
group, sirloimus-eluting stent with 6–12 months of follow-up; cholesterol (CHO); triglyceride (TG); high-density lipoprotein
cholesterol (HDL); low-density lipoprotein cholesterol (LDL); OCT, optical coherence tomography; left anterior descending artery
(LAD); left circumflex artery (LCX); right coronary artery (RCA).*Within three groups, p,0.0001; BMS1 vs SES, p=NS.
Table 2 OCT findings
Finding BMS1 (n=7) BMS2 (n=6) SES (n=10) p Value
No of stents 8 6 13
Total stent struts 1465 1242 2425
Side branch struts 3 7 24
Complete apposition 1462 1235 2358 ,0.0001*
Incomplete apposition 0 0 43
Strut covered 1457 1231 1990 ,0.0001**
Strut uncovered 5 4 368
Maximal NIT (mm) 0.59 (0.36) 0.61 (0.27) 0.12 (0.07) ,0.0001{
Minimal NIT (mm) 0.20 (0.18) 0.22 (0.15) 0.04 (0.02) ,0.0001{
* SES vs BMS1 and BMS2, p ,0.0001;**SES vs BMS1 and BMS2, p,0.0001; {within three groups, p,0.0001, BMS1 vs BMS2,
p=NS;{within three groups, p,0.0001, BMS1 vs BMS2, p=0.028.
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the SES group. No significant differences were found in the
demographic or baseline characteristics, including coronary risk
factors, between the groups (table 1).The implanted stent
diameters and lengths among three groups were also not
significantly different.
OCT imaging
The OCT findings are summarised in table 2.
The total number of stent struts evaluated was 1465 struts in
the BMS1 group, 1242 in the BMS2 group and 2425 in the SES
group. Of all the stent struts, three stent struts within the open
bifurcation artery were completely surrounded by thrombus in
the BMS1 group; six struts were surrounded by thrombus and
one strut was surrounded by a thin tissue fusing with vessel
wall in the BMS2 group; and 24 struts observed within the open
bifurcation artery in the SES group showed complex conditions,
including a few struts surrounded by thrombus, others
surrounded by a thick tissue layer (fig 1A), and the remaining
almost uncovered. Significant differences among the percen-
tages of completely apposed stent struts (100%, 100% and 98%,
in the BMS1, BMS2 and SES groups, respectively; BMS1 vs SES
p,0.0001; BMS2 vs SES p,0.0001) and covered stent struts
(99.7%, 99.7% and 83%, in the BMS1, BMS2 and SES groups,
Figure 1 (A) OCT image of stent struts surrounded by a thick tissue
that fuses with vessel wall in an open bifurcation artery in SES 12-month
follow-up (red arrow). (B) OCT imaging visualised of uncovered struts
(red arrow) in SES 12-month follow-up.
Figure 2 (A) OCT image showing struts surrounded by
hyperproliferative neointimal growth which led to re-stenosis 5 months
after BMS stenting. (B) OCT image of well apposed stent struts with a
thin neointimal formation around stent 12 months after SES stenting.
Interventional cardiology
568 Heart 2008;94:566–570. doi:10.1136/hrt.2007.118679respectively; BMS1 vs SES p,0.0001; BMS2 vs SES p,0.0001)
(figs 1, 2A, 2B) were found among the three groups, but there
was no significant difference between the BMS1 and BMS2
groups. The mean maximal and minimal NIT measured in the
SES group were all significantly less than that of BMS1 or BMS2
(p,0.0001), the minimal NIT in the BMS1 group was
significantly less than the BMS2, but mean maximal NIT was
no significant difference between the BMS1 and BMS2.
One patient experienced acute anterior myocardial infarction
(AMI) after SES stenting (Cypher) in the LAD at 29-month
follow-up. Fifteen days after AMI, coronary angiography
showed no significant stenosis in LAD with TIMI grade 3 flow.
OCT examination of the LAD showed irregular stent strut
separation, stent malapposition, thrombus surrounding the
surfaces of stent struts and a dilated coronary artery within the
stented segment (fig 3).
DISCUSSION
With the development of percutaneous coronary intervention
(PCI), intracoronary stenting has become the treatment of
choice for patients with focal coronary artery disease. Until
about five years ago, bare-metal stents were applied widely in
PCI, but a major problem with re-stenosis resulting from
hyperproliferative neointimal growth became apparent in a
significant proportion of patients 3–6 months after stenting,
especially for patients with high coronary risk factors. In the era
of drug-eluting stents such as sirolimus-eluting stents, re-
stenosis rates have been reduced dramatically for high-risk
patients, but one of the major concerns is the biocompatibility
of these stent systems. Evidence from recent studies suggests
that the anti-proliferative effects of SES delay re-endothelialisa-
tion within the stent, increasing the risk of stent thrombosis.
11–13
Late or very late thrombosis after SES stenting is related to lack
of the stent strut endothelial coverage. In order to understand
and control the in vivo processes that take place after SES
implantation, additional new tools are needed beyond angio-
graphic guidance.
OCT is a catheter-based technology producing images from
backscattered ‘‘echoes’’ similar to intravascular ultrasound
(IVUS), but using a near-infrared, high-bandwidth light source.
This new technology provides ultra-high resolution (10 mm) for
in vivo endovascular visualisation. Ex vivo studies have shown
resolution capabilities of 2–10 mm, which provide the necessary
definition to identify the key elements of vulnerable plaques,
including the thin fibrous cap, lipid-rich core and high
macrophage content.
371 41 5This new imaging method is also
capable of detecting several different features of intravascular
pathology, such as previous disruption of fibrous caps of lipid-
rich plaques, the presence of the intracoronary thrombosis, the
depth of dissections caused by balloon inflations that can not be
fully appreciated by IVUS, cuts in the atherosclerotic plaque
made by the blades of a cutting balloon, tissue protruding
through stent struts and underdeployed struts otherwise missed
by IVUS. Several studies have demonstrated the feasibility of
intravascular OCT for obtaining qualitative information for
characterisation of coronary atherosclerotic plaques and for
evaluation of intracoronary stenting.
5689
In the present study, we employed OCT to analyse strut
apposition and neointimal coverage of BMS and SES at follow-
up in 24 patients with coronary artery disease. In BMS, OCT
images showed all stent struts with complete apposition, with
almost all strut surfaces covered by neointima, as well as some
struts covered by hyperproliferative neointima, which resulted
in re-stenosis. In the 5–10-month and 23–93-month follow-up
groups, the strut apposition, strut coverage, and maximal NIT
were not significantly different. These results indicate that strut
apposition and neointimal thickness were stable in BMS
5 months after stenting. Compared with BMS, SES visualised
by OCT had more incomplete apposition, with more struts
uncovered and thinner NIT. These results verify the results of
numerous earlier studies that show SES can significantly reduce
neointimal growth and re-stenosis in the short-term follow-up.
However, more SES stent struts were uncovered or malapposed
compared to BMS stent struts. Both of these conditions may
lead to late or very late thrombosis.
One patient in our study experienced an acute anterior
myocardial infarction 29 months after the implantation of a
sirolimus-eluting stent. This patient had been imaged using
OCT 14 days after AMI. Although coronary angiography did
not find any evidence of restenosis or thrombosis, intracoronary
OCT revealed irregular strut separation and fibrin-rich throm-
bus. The precise mechanisms related to the stent malapposition
and late thrombosis in this case are unknown. A recent report
from Virmani et al describes the first case of fatal acute
myocardial infarction and cardiac rupture resulting from late
thrombosis of a Cypher stent deployed 18 months previously.
16
The autopsy in the case reported by Virmani et al showed an
aneurysm in the wall of the stented artery, with extensive
inflammatory infiltration consisting of lymphocytes, plasma
cells, macrophages and eosinophils invading the intima, media
and adventitia. The luminal surface of the proximal stent was
surrounded by fibrin-rich thrombus with sparse smooth muscle
cells, and the luminal surfaces of the proximal and distal stents
were focally malapposed, with thick layers of fibrin thrombus
separating the stent from the underlying plaque and arterial
wall. The authors concluded that localised hypersensitivity
vasculitis developed in response to the polymer of the Cypher
coronary stent was the most likely mechanism. The OCT
Figure 3 OCT image clearly showed strut surrounded by thrombus (red
arrow).
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of the autopsy reported by Virmani et al.
16
From these findings of OCT imaging in SES or BMS, we
conclude that long-term strut malapposition and the lack of
neointimal coverage of stent struts may be responsible for late
or very late thrombosis, and that enhanced surveillance of
patients with SES may help avoid some of the observed late
complications with SES. Moreover, continued efforts to
improve polymer biocompatibility in SES are warranted.
Limitations
OCT imaging has some limitations in clinical situations, one of
which is its inability to image through blood. Therefore, it is
necessary to establish a blood-free environment for OCT light
to penetrate to the tissue. Although clear OCT imaging was
obtained by the use of OBC balloon blocking blood flow, the
need to occlude blood limits the clinical application of OCT,
especially for patients with left main disease, ostial disease,
congestive heart failure and very tortuous lesions. Another
limitation is the limited depth of penetration of OCT, which is
1.5–2.0 mm. The 10 mm resolution of OCT means that stents
with 10 mm of very early re-endothelial coverage may have
unknowingly been categorised as uncovered in this study. The
second generation OCT imaging system may eliminate many of
the technical limitations of the present study.
Competing interests: None.
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